↓ Skip to main content

Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma

Overview of attention for article published in Journal for Immunotherapy of Cancer, June 2021
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (74th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (51st percentile)

Mentioned by

twitter
10 X users

Readers on

mendeley
81 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Article details
Title
Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma
Published in
Journal for Immunotherapy of Cancer, June 2021
DOI 10.1136/jitc-2020-002057
Pubmed ID
Authors

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Activity
Login to access the full charts related to this output.
X Demographics

X Demographics

The data shown below were collected from the profiles of 10 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 81 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Login to view Mendeley reader trends over time.

Geographical breakdown

Geographical breakdown
Country Count As %
Unknown 81 100%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Student > Ph. D. Student 9 11%
Researcher 9 11%
Student > Master 5 6%
Other 3 4%
Student > Doctoral Student 2 2%
Other 4 5%
Unknown 49 60%
Readers by discipline
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 8 10%
Medicine and Dentistry 6 7%
Pharmacology, Toxicology and Pharmaceutical Science 4 5%
Immunology and Microbiology 4 5%
Chemistry 3 4%
Other 7 9%
Unknown 49 60%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 June 2021.
All research outputs
#7,334,713
of 34,517,649 outputs
Outputs from Journal for Immunotherapy of Cancer
#1,935
of 4,748 outputs
Outputs of similar age
#125,585
of 488,523 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#79
of 164 outputs
Altmetric has tracked 34,517,649 research outputs across all sources so far. Compared to these this one has done well and is in the 78th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,748 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.3. This one has gotten more attention than average, scoring higher than 59% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 488,523 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.
We're also able to compare this research output to 164 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 51% of its contemporaries.